Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.800
+0.040 (2.27%)
At close: May 12, 2025, 4:00 PM
1.800
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
Rein Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
39.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNTX News
- 11 days ago - Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire
- 12 days ago - Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - PRNewsWire
- 14 days ago - Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference - PRNewsWire
- 19 days ago - Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases - PRNewsWire
- 27 days ago - Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - PRNewsWire
- 5 weeks ago - Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire